Growth hormone treatment in dilated cardiomyopathy.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Treatment with human recombinant growth hormone (GH) has yielded conflicting results in patients with congestive heart failure.

The researchers analyzed the baseline somatotrophic axis in 50 patients with dilated cardiomyopathy.

Who Took Part

The study group was 50 patients.

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

The primary end-points were the effect on left ventricular (LV) mass and systolic wall stress.

The secondary endpoint was LV ejection fraction.

Topics PubMed links to this paper include Biomarkers, Cardiomyopathy, Dilated, Growth Hormone, Heart Ventricles, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Regression Analysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 50 patients.

The publication is from 2002 (Journal of cardiac surgery), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.